Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer.
BACKGROUND
A blood pressure drop after bevacizumab administration and its clinical significance have not been previously reported.


METHODS
Blood pressure data at 0, 90, and 180 min after a total of 162 bevacizumab administrations in 81 advanced colorectal cancer patients were retrospectively investigated.


RESULTS
Twenty-five patients (30%) demonstrated an average temporary drop of 20 mm Hg or more in systolic blood pressure. We classified these 25 patients as group A and the others as group B. Median time-to-treatment failure (TTF) was significantly longer in group A than in group B (291 vs 162 days; P=0.02). Furthermore, the proportion of patients who required intervention with antihypertensive drugs during bevacizumab treatment was significantly higher in group A than in group B (36% vs 4%; P<0.01).


CONCLUSIONS
This study suggests that a temporary blood pressure drop after bevacizumab administration could be a predictive marker for bevacizumab treatment.
Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogin-Kawahara-cho, Sakyo-ku, Kyoto, Japan. kanai@kuhp.kyoto-u.ac.jp
M
M
Kanai
H
H
Ishiguro
Y
Y
Mori
T
T
Kitano
T
T
Nishimura
S
S
Matsumoto
K
K
Yanagihara
T
T
Chiba
M
M
Toi
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D001794:Blood Pressure / Q000187:drug effects*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D017211:Treatment Failure
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D000068258:Bevacizumab